Table 1.
Patients’ main characteristics.
|
Patients’ Number
(female–male) |
38 (15 F—23 M) |
| Mean/median age (Range) | 59.4 ± 10.3 y/58 y (35–79) |
| Mean/median administred activity (range) | 29 ± 1.5 GBq/29 GBq (23.9–32.8) |
| Mean/median PRRT cycles (range) | 5.3 ± 0.5/5 (5–7) |
| GEP NET origin | |
| Pancreas | 17/38 (45%) |
| Ileum | 14/38 (37%) |
| Colon | 3/38 (8%) |
| Stomach | 2/38 (5%) |
| Jejunum | 2/38 (5%) |
| Grading (n) | |
| G1 | 9/38 (23.7%) |
| G2 | 27/38 (71%) |
| G3 | 2/38 (5.3%) |
| Lesions’ distribution | |
| Bone Lesions | 42/324 (12.9%) |
| Lymph nodal Lesions | 91/324 (28.1%) |
| Liver Lesions | 169/324 (52.2%) |
| Parenchimal Lesions (no liver) | 22/324 (6.8%) |
| Singular lesion response to PRRT | |
| PD | 133/324 (41%) |
| SD | 79/324 (24.4%) |
| PR | 92/324 (28.4%) |
| CR | 20/324 (6.2%) |
| Lesions’ distribution according to response (SD, PR, CR) and grading | |
| G1 | 28/82 (34.1%) |
| G2 | 157/232 (67.7%) |
| G3 | 6/10 (60%) |
| Scanner types | n patients—n lesions |
| GE Discovery 690 | 15/38—135/324 |
| Siemens biograph horizon | 14/38—133/324 |
| GE Discovery ST | 4/38—34/324 |
| Philips Gemini GXL 16 | 4/38—18/324 |
| GE Discovery 600 | 1/38—4/324 |